노인황반변성(AMD) 시장 : 약물 유형별, 질병 유형별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2023-2032년)

According to a new report published by Allied Market Research, titled, "Age Related Macular Degeneration (AMD) Market," The age related macular degeneration (amd) market was valued at $9.4 billion in 2022, and is estimated to reach $15.4 billion by 2032, growing at a CAGR of 5% from 2023 to 2032.

However, high cost associated with age related macular degeneration drugs is projected to impede the market growth in upcoming years. On the contrary, increase in R&D activities in age-related macular degeneration (AMD) treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.

The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global age-related macular degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the age related macular degeneration (amd) market analysis from 2022 to 2032 to identify the prevailing age related macular degeneration (amd) market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the age related macular degeneration (amd) market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global age related macular degeneration (amd) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

• Aflibercept
• Ranibizumab
• Others

By Disease Type

• Wet Age Related Macular Degeneration (AMD)
• Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • Spain
  • UK
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• F. Hoffmann-La Roche Ltd.
• Coherus Biosciences Inc
• Biogen
• Regeneron Pharmaceuticals Inc.
• Ionis Pharmaceuticals, Inc.
• Novartis AG
• Bayer AG
• Bausch Health Companies Inc.
• Apellis Pharmaceuticals Inc.
• Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Bargaining power of suppliers
  • 3.3.2. Bargaining power of buyers
  • 3.3.3. Threat of substitutes
  • 3.3.4. Threat of new entrants
  • 3.3.5. Intensity of rivalry
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in geriatric population
    • 3.4.1.2. Increase in incidences of age-related macular degeneration (AMD) across the globe

• 3.4.2. Restraints
  • 3.4.2.1. High cost of treatment

• 3.4.3. Opportunities
  • 3.4.3.1. Increase in number of pipelines drug

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Aflibercept
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Ranibizumab
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Wet Age Related Macular Degeneration (AMD)
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Dry Age Related Macular Degeneration (AMD)
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital Pharmacy
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Retail Pharmacy
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Online Pharmacy
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Drug Type
  • 7.2.3. Market size and forecast, by Disease Type
  • 7.2.4. Market size and forecast, by Distribution Channel
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Drug Type
    • 7.2.5.1.3. Market size and forecast, by Disease Type
    • 7.2.5.1.4. Market size and forecast, by Distribution Channel
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Drug Type
    • 7.2.5.2.3. Market size and forecast, by Disease Type
    • 7.2.5.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Drug Type
    • 7.2.5.3.3. Market size and forecast, by Disease Type
    • 7.2.5.3.4. Market size and forecast, by Distribution Channel
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Drug Type
  • 7.3.3. Market size and forecast, by Disease Type
  • 7.3.4. Market size and forecast, by Distribution Channel
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. France
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Drug Type
    • 7.3.5.1.3. Market size and forecast, by Disease Type
    • 7.3.5.1.4. Market size and forecast, by Distribution Channel
    • 7.3.5.2. Germany
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Drug Type
    • 7.3.5.2.3. Market size and forecast, by Disease Type
    • 7.3.5.2.4. Market size and forecast, by Distribution Channel
    • 7.3.5.3. Italy
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Drug Type
    • 7.3.5.3.3. Market size and forecast, by Disease Type
    • 7.3.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5.4. Spain
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Drug Type
    • 7.3.5.4.3. Market size and forecast, by Disease Type
    • 7.3.5.4.4. Market size and forecast, by Distribution Channel
    • 7.3.5.5. UK
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Drug Type
    • 7.3.5.5.3. Market size and forecast, by Disease Type
    • 7.3.5.5.4. Market size and forecast, by Distribution Channel
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Drug Type
    • 7.3.5.6.3. Market size and forecast, by Disease Type
    • 7.3.5.6.4. Market size and forecast, by Distribution Channel
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Drug Type
  • 7.4.3. Market size and forecast, by Disease Type
  • 7.4.4. Market size and forecast, by Distribution Channel
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. China
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Drug Type
    • 7.4.5.1.3. Market size and forecast, by Disease Type
    • 7.4.5.1.4. Market size and forecast, by Distribution Channel
    • 7.4.5.2. Japan
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Drug Type
    • 7.4.5.2.3. Market size and forecast, by Disease Type
    • 7.4.5.2.4. Market size and forecast, by Distribution Channel
    • 7.4.5.3. Australia
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Drug Type
    • 7.4.5.3.3. Market size and forecast, by Disease Type
    • 7.4.5.3.4. Market size and forecast, by Distribution Channel
    • 7.4.5.4. India
    • 7.4.5.4.1. Key market trends, growth factors and opportunities
    • 7.4.5.4.2. Market size and forecast, by Drug Type
    • 7.4.5.4.3. Market size and forecast, by Disease Type
    • 7.4.5.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Key market trends, growth factors and opportunities
    • 7.4.5.5.2. Market size and forecast, by Drug Type
    • 7.4.5.5.3. Market size and forecast, by Disease Type
    • 7.4.5.5.4. Market size and forecast, by Distribution Channel
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Key market trends, growth factors and opportunities
    • 7.4.5.6.2. Market size and forecast, by Drug Type
    • 7.4.5.6.3. Market size and forecast, by Disease Type
    • 7.4.5.6.4. Market size and forecast, by Distribution Channel
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Drug Type
  • 7.5.3. Market size and forecast, by Disease Type
  • 7.5.4. Market size and forecast, by Distribution Channel
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Drug Type
    • 7.5.5.1.3. Market size and forecast, by Disease Type
    • 7.5.5.1.4. Market size and forecast, by Distribution Channel
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Drug Type
    • 7.5.5.2.3. Market size and forecast, by Disease Type
    • 7.5.5.2.4. Market size and forecast, by Distribution Channel
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Drug Type
    • 7.5.5.3.3. Market size and forecast, by Disease Type
    • 7.5.5.3.4. Market size and forecast, by Distribution Channel
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Drug Type
    • 7.5.5.4.3. Market size and forecast, by Disease Type
    • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. Regeneron Pharmaceuticals Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
• 9.2. Novartis AG
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. F. Hoffmann-La Roche Ltd.
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Biogen
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Bayer AG
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
• 9.6. Coherus Biosciences Inc
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Sanofi S.A.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
• 9.8. Apellis Pharmaceuticals Inc.
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Bausch Health Companies Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Ionis Pharmaceuticals, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance